Literature DB >> 20796235

The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity.

Sara G A van Velsen1, Mirjam J Knol, Inge M Haeck, Carla A F M Bruijnzeel-Koomen, Suzanne G M A Pasmans.   

Abstract

The Self-Administered Eczema Area and Severity Index (SA-EASI) is one of the few patient based atopic dermatitis (AD) disease activity scores and was found to be highly correlated with the EASI. Correlation with other frequently used scoring methods has not been investigated. The aim of this study was to evaluate the relation of the SA-EASI with two physician-based disease activity scores (objective SCORAD and SASSAD score) and with a serum marker for AD (Thymus and Activation-Regulated Cytokine [TARC]) in children with AD. Sixty children with moderate to severe AD were included. The SA-EASI was completed by caregivers, and the objective SCORAD and SASSAD scores were measured successively on the same day by a trained investigator. Blood for serum TARC measurement was drawn. The correlation between the SA-EASI and the objective SCORAD was high (ρ = 0.61, p = <0.001), mainly based on high correlation between the body surface area (BSA) measurements of both scores (ρ = 0.50, p = <0.001). The correlation with the SASSAD score (only severity measurement) was 0.43 (p = <0.001). The correlation with serum TARC levels was 0.46; p = <0.001, mainly based on the BSA score of the SA-EASI (ρ = 0.42, p = <0.001). Parents may have more difficulty in scoring severity of AD than scoring BSA involved. Educating parents in severity scoring of AD may improve agreement of the SA-EASI and the objective SCORAD, TARC, and SASSAD score. Additional use of the SA-EASI in routine clinical practice or in trials may then facilitate more frequent but still accurate assessment of AD.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20796235     DOI: 10.1111/j.1525-1470.2010.01285.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  5 in total

Review 1.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2013-11-27       Impact factor: 11.527

2.  Comparing high altitude treatment with current best care in Dutch children with moderate to severe atopic dermatitis (and asthma): study protocol for a pragmatic randomized controlled trial (DAVOS trial).

Authors:  Karin B Fieten; Wieneke T Zijlstra; Harmieke van Os-Medendorp; Yolanda Meijer; Monica Uniken Venema; Lous Rijssenbeek-Nouwens; Monique P l'Hoir; Carla A Bruijnzeel-Koomen; Suzanne G M A Pasmans
Journal:  Trials       Date:  2014-03-26       Impact factor: 2.279

3.  The expert network and electronic portal for children with respiratory and allergic symptoms: rationale and design.

Authors:  Kim Zomer-Kooijker; Francine C van Erp; Walter A F Balemans; Bart E van Ewijk; Cornelis K van der Ent
Journal:  BMC Pediatr       Date:  2013-01-16       Impact factor: 2.125

4.  Warm, humid, and high sun exposure climates are associated with poorly controlled eczema: PEER (Pediatric Eczema Elective Registry) cohort, 2004-2012.

Authors:  Michael R Sargen; Ole Hoffstad; David J Margolis
Journal:  J Invest Dermatol       Date:  2013-06-17       Impact factor: 8.551

5.  Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review.

Authors:  Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg
Journal:  J Invest Dermatol       Date:  2021-08-02       Impact factor: 8.551

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.